Literature DB >> 28413969

Optimizing the Management of Uncontrolled Hypertension: What do Triple Fixed-Dose Drug Combinations Add?

Costas Thomopoulos1, Georgios Katsimagklis2, Stefanos Archontakis1, Georgios Skalis1, Thomas Makris1.   

Abstract

Fixed-dose triple drug combinations represent one of the latest innovations of pharmacotherapy for hypertension (HT). They combine a traditional renin-angiotensin system blocker, a diuretic and a calcium channel blocker. The main benefit is the simplification of treatment regimen because 3 different agents are combined at different doses in a single pill. Improving adherence to treatment partly explains why this kind of combination may effectively reduce blood pressure (BP). BP lowering by a single- pill triple-drug combination can be approximately predicted, by using appropriate formulas described in previous meta-analysis of randomized trials. Thus, clinicians may select the appropriate dose for each of the combined drugs. Selection of different types of fixed-dose triple-drug combinations relies upon clinical experience, commercial availability and evidence from clinical trials and metaanalyses for each agent alone. However, triple fixed-dose drug combinations should be reserved only for patients with uncontrolled BP with 2 agents, poor adherence in complex therapeutic regimens or on inappropriate free-drug combinations. Also, triple therapy may help overcome clinical inertia by prescribing more potent antihypertensive formulations in one pill. In contrast, this type of multiple-drug fixed-dose combination might be less safe in very old and frail patients, as well as in those with chronic kidney disease. Although new combinations may help overcome the clinical inertia of achieving individualized BP targets, doctors should also pay attention reinforcement of lifestyle changes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Fixed-drug combination; bloodzzm321990pressure lowering; blood pressure; hypertension; resistant hypertension; uncontrolled hypertension

Mesh:

Substances:

Year:  2017        PMID: 28413969     DOI: 10.2174/1570161115666170414115301

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  2 in total

Review 1.  Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA).

Authors:  Nicolás Renna; Daniel Piskorz; Diego Stisman; Diego Martinez; Ludmila Lescano; Sergio Vissani; Walter Espeche; Diego Marquez; Roberto Parodi; Diego Naninni; Marcos Baroni; Daniel Llanos; Rocio Martinez; Jessica Barochinner; Gustavo Staffieri; Fernando Lanas; Mónica Velásquez; Marcos Marin; Bryan Williams; Irene Ennis
Journal:  J Hum Hypertens       Date:  2021-06-04       Impact factor: 3.012

2.  Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study.

Authors:  Sergey A Boytsov; Yuri P Burtsev; Yunona V Khomitskaya; Yuri A Karpov
Journal:  Adv Ther       Date:  2021-05-15       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.